Small Molecules for Cancer or Autoimmunity Icon

Cambridge Healthtech Institute’s 4th Annual

Small Molecule Immuno-Modulators

Combatting Cancer, Autoimmunity and Inflammation with the Immune System

April 11-12, 2023

 

Evidence of the role of the immune system in many diseases continues to mount. Many of the targets are intracellular – which means they are accessible only to small molecule modulators, as opposed to biologics. CHI’s 4th Annual Small Molecule Immuno-Modulators conference will cover small molecule compounds that either activate or dampen the immune system to fight diseases such as cancer (via immuno-oncology (IO)), autoimmunity, neurodegeneration, and inflammation-related disorders. Join fellow discovery chemists to share and rejoice in the renaissance of small molecule approaches that are enabling progress in an area of drug discovery that was most recently the domain of biologics.

 

Coverage will likely include:

 

  • Remodeling the tumor microenvironment (TME) with small molecule modulators
  • Small molecule T cell checkpoint inhibitors
  • Modulating tumor-associated macrophages (TAMs) with small molecules
  • Inflammatory bowel disease (IBD) small molecule drug candidates
  • Autoimmune disease small molecule drug leads and candidates
  • Updates on new intracellular kinase inhibitors for autoimmune diseases
  • Dual cancer/autoimmune targets (STING, NLRP3, RIG1)
  • Neuro- and regular inflammation targets (LRRK2, MIF, BTK)

 

The deadline for priority consideration is September 23, 2022.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

We hope you can join us for the 5 concurrent day-and-a-half conferences during each half of our 18th Annual Drug Discovery Chemistry event. Registering for this conference lets you also move back and forth among parallel programs to create your own agenda.

 

Opportunities for Participation:

 

 

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director and Lead Content Director for Drug Discovery Chemistry

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431

Email: kskahan@healthtech.com